|Dr. Jan-Anders Karlsson||Chief Exec. Officer & Exec. Director||N/A||N/A||1955|
|Mr. Piers John Morgan MA, ACA||Chief Financial Officer||106.79k||N/A||1966|
|Ms. Claire Louise Poll||Legal Counsel||N/A||N/A||1967|
|Dr. Peter Spargo Ph.D.||Sr. VP of CMC||257.53k||N/A||1962|
|Mr. Richard Hennings||Commercial Director||N/A||N/A||1970|
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Verona Pharma plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.